Juan W Valle Selected Research

Biliary Tract Neoplasms (Biliary Tract Cancer)

3/2022	Targeted Therapies for Perihilar Cholangiocarcinoma.
1/2022	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.
1/2022	Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy.
10/2021	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
7/2021	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis.
4/2021	Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
1/2021	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).
1/2021	Outcomes in older patients with biliary tract cancer.
1/2021	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
1/2021	Biliary tract cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Juan W Valle Research Topics

Disease

56	Neoplasms (Cancer) 05/2022 - 04/2007
27	Biliary Tract Neoplasms (Biliary Tract Cancer) 03/2022 - 07/2014
23	Cholangiocarcinoma 01/2022 - 04/2015
19	Adenocarcinoma 05/2022 - 01/2006
19	Pancreatic Neoplasms (Pancreatic Cancer) 05/2022 - 01/2006
18	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2021 - 12/2011
15	Disease Progression 01/2022 - 10/2011
13	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2014
11	Carcinoid Tumor (Carcinoid) 01/2022 - 01/2013
8	Gallbladder Neoplasms (Gallbladder Cancer) 01/2022 - 01/2018
8	Diarrhea 01/2022 - 11/2016
8	Fatigue 10/2021 - 08/2015
7	Hepatocellular Carcinoma (Hepatoma) 02/2022 - 01/2014
5	Infections 01/2021 - 03/2016
5	Neuroendocrine Carcinoma 01/2020 - 01/2019
5	Stomatitis 01/2020 - 03/2016
4	Hypertension (High Blood Pressure) 10/2021 - 05/2014
4	Neutropenia 10/2021 - 10/2011
4	Carcinoma (Carcinomatosis) 01/2021 - 01/2017
4	Exanthema (Rash) 01/2020 - 02/2016
4	Colorectal Neoplasms (Colorectal Cancer) 11/2018 - 01/2007
3	Thrombocytopenia (Thrombopenia) 10/2021 - 01/2017
3	Margins of Excision 06/2019 - 02/2014
3	Primitive Neuroectodermal Tumors (PNET) 01/2018 - 12/2014
2	Frailty 01/2022 - 01/2021
2	Ascites 11/2021 - 01/2020
2	Hyperglycemia 01/2021 - 01/2018
2	Nausea 01/2021 - 01/2017
2	Weight Loss (Weight Reduction) 12/2020 - 01/2018
2	Fever (Fevers) 08/2020 - 04/2007
2	Jaundice (Icterus) 08/2020 - 09/2015
2	Ovarian Neoplasms (Ovarian Cancer) 06/2020 - 11/2018
2	Bile Duct Neoplasms (Bile Duct Cancer) 07/2015 - 07/2012
1	Inflammation (Inflammations) 05/2022
1	Klatskin Tumor 03/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Hepatitis 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Sclerosing Cholangitis 01/2022
1	Choledocholithiasis 01/2022
1	Overweight 01/2022
1	Obesity 01/2022
1	Liver Diseases (Liver Disease) 01/2022
1	Lung Diseases (Lung Disease) 01/2022

Drug/Important Bio-Agent (IBA)

22	Gemcitabine FDA Link 11/2021 - 01/2006
16	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2013
11	Everolimus FDA Link 01/2022 - 12/2014
11	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 01/2006
9	Capecitabine (Xeloda)FDA Link 01/2022 - 05/2008
9	Pharmaceutical PreparationsIBA 09/2021 - 12/2011
7	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2022 - 12/2016
7	Fluorouracil (Carac)FDA LinkGeneric 11/2021 - 01/2007
6	Sunitinib (Sutent)FDA Link 04/2019 - 12/2011
5	telotristat ethylIBA 01/2022 - 12/2016
5	Leucovorin (Folinic Acid)FDA Link 01/2021 - 09/2010
4	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 11/2021 - 01/2020
4	ivosidenibIBA 11/2021 - 01/2020
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 01/2007
4	Cetuximab (Erbitux)FDA Link 01/2020 - 01/2007
3	Sorafenib (BAY 43-9006)FDA Link 02/2022 - 01/2014
3	BilirubinIBA 01/2021 - 07/2015
3	NUC-1031IBA 01/2021 - 06/2020
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2014
3	Bevacizumab (Avastin)FDA Link 11/2018 - 01/2007
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2018 - 05/2014
3	AcidsIBA 02/2018 - 01/2014
3	Tryptophan HydroxylaseIBA 01/2018 - 12/2016
3	Tyrosine Kinase InhibitorsIBA 01/2017 - 05/2014
2	folfirinoxIBA 05/2022 - 10/2020
2	6-propylchromone-2-carboxylic acid (PCCA)IBA 03/2022 - 01/2022
2	Biological ProductsIBA 01/2022 - 01/2020
2	Cytidine DeaminaseIBA 11/2021 - 06/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 08/2016
2	TOR Serine-Threonine KinasesIBA 01/2021 - 12/2014
2	TransferasesIBA 01/2021 - 01/2017
2	Adenosine Monophosphate (AMP)IBA 09/2020 - 01/2018
2	AntigensIBA 01/2020 - 07/2015
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 01/2007
2	Alkaline PhosphataseIBA 10/2019 - 01/2017
2	cediranib (AZD2171)IBA 01/2018 - 08/2015
2	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2018 - 01/2014
2	ErbB Receptors (EGF Receptor)IBA 04/2017 - 01/2017
2	AZD 6244IBA 06/2016 - 02/2016
2	pro-brain natriuretic peptide (1-76)IBA 01/2014 - 01/2013
2	Monoclonal AntibodiesIBA 05/2008 - 04/2007
1	Interleukin-6 (Interleukin 6)IBA 02/2022
1	InterleukinsIBA 02/2022
1	Oncostatin MIBA 12/2021
1	Oncostatin M Receptors (Oncostatin M Receptor)IBA 12/2021
1	Messenger RNA (mRNA)IBA 11/2021

Therapy/Procedure

43	Therapeutics 03/2022 - 01/2014
38	Drug Therapy (Chemotherapy) 05/2022 - 01/2006
9	Adjuvant Chemotherapy 01/2020 - 09/2010
5	Radiotherapy 09/2021 - 04/2015
4	Immunotherapy 07/2021 - 01/2020
3	Stents 08/2020 - 03/2008
2	Neoadjuvant Therapy 01/2022 - 08/2019
2	Aftercare (After-Treatment) 10/2021 - 08/2016
2	Precision Medicine 09/2020 - 01/2017
2	Intravenous Infusions 01/2017 - 10/2011